-
Mashup Score: 2AlloVir to merge with Kalaris Therapeutics - 2 month(s) ago
AlloVir, an allogeneic T cell immunotherapy company, will merge with Kalaris Therapeutics to focus on retinal diseases, according to a press release.The merger is expected to close in the first quarter of 2025, with the combined company estimated to have about $100 million in cash to operate into the fourth quarter of 2026. The company, which will operate as Kalaris Therapeutics, will focus on
Source: www.healio.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0VIDEO: EYP-1901 shows maintenance of visual acuity, reduced treatment burden at 12 months - 3 month(s) ago
In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, of Retina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.
Source: www.healio.comCategories: General Medicine News, OphthalmologyTweet-
The DAVIO 2 trial investigating EYP-1901 is the largest intravitreal tyrosine kinase inhibition trial to date. David Eichenbaum, MD, shared promising 12-month results with @GoHealio 🎥👇 #OcularSurgeryNews #Ophthalmology #Retina https://t.co/lSeqKAYmu8 https://t.co/X8aTCym1dt
-
❗ICYMI❗ AlloVir, an allogeneic T cell immunotherapy company, will merge with Kalaris Therapeutics to focus on retinal diseases. More details 🔗👇 #OcularSurgeryNews #Ophthalmology #Retina https://t.co/wqKozYgOYD https://t.co/gzsmCSsqAA